Inhibition of IL-17 with the monoclonal antibody ixekizumab blocks this recruitment and has been shown to lead to the remission of symptoms in as many as 90% of plaque psoriasis patients receiving injections every 4 weeks. Here, IL17A is linked to psoriasis vulgaris.